Skip to main content
SpringerLink
Log in

Therapy

Immunotherapy for T1DM—targeting innate immunity

  • News & Views
  • Published:

From Nature Reviews Endocrinology

View current issue Sign up to alerts

Two trials have assessed the use of canakinumab and anakinra in patients with new-onset type 1 diabetes mellitus (T1DM). Although fairly safe, the drugs were not efficacious in terms of halting the decline in β-cell function. Is this the end of the line for targeting IL-1 in T1DM?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: IL-1 secretion and action on islet β cells.

References

  1. Harjutsalo, V., Sjöberg, L. & Tuomilehto, J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 371, 1777–1782 (2008).

    Article  Google Scholar 

  2. Moran, A. et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet http://dx.doi.org/10.1016/S0140-6736(13)60023-9.

  3. Maedler, K. et al. Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 110, 851–860 (2002).

    Article  CAS  Google Scholar 

  4. Kim, S. et al. Apoptosis of human islet cells by cytokines. Immune Netw. 12, 113–117 (2012).

    Article  Google Scholar 

  5. Mills, K. H., Dungan, L. S., Jones, S. A. & Harris, J. The role of inflammasome-derived IL-1 in driving IL-17 responses. J. Leukoc. Biol. 93, 489–497 (2013).

    Article  CAS  Google Scholar 

  6. Pipeleers, D. et al. Role of pancreatic β-cells in the process of β-cell death. Diabetes 50 (Suppl. 1), S52–S57 (2001).

    Article  CAS  Google Scholar 

  7. Mandrup-Poulsen, T., Pickersgill, L. & Donath, M. Y. Blockade of interleukin 1 in type 1 diabetes mellitus. Nat. Rev. Endocrinol. 6, 158–166 (2010).

    Article  CAS  Google Scholar 

  8. Dinarello, C. A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117, 3720–3732 (2011).

    Article  CAS  Google Scholar 

  9. Wen, L. et al. In vivo diabetogenic action of CD4+ T lymphocytes requires Fas expression and is independent of IL-1 and IL-18. Eur. J. Immunol. 41, 1344–1351 (2011).

    Article  CAS  Google Scholar 

  10. Ablamunits, V. et al. Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes 61, 145–154 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Diabetes Research Group, Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Heath Park, Cardiff, CF14 4XN, UK

    F. Susan Wong

  2. Department of Medicine, Section of Endocrinology, Yale School of Medicine, 333 Cedar Street, New Haven, 06520, CT, USA

    Li Wen

Authors
  1. F. Susan Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Li Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Susan Wong.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wong, F., Wen, L. Immunotherapy for T1DM—targeting innate immunity. Nat Rev Endocrinol 9, 384–385 (2013). https://doi.org/10.1038/nrendo.2013.103

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2013.103

  • Springer Nature Limited

This article is cited by

Search

Navigation